Inverse micellar sugar glass (IMSG) nanoparticles for transfollicular vaccination

Karande, 2010, Transcutaneous immunization: an overview of advantages, disease targets, vaccines, and delivery technologies, Annu. Rev. Chem. Biomol. Eng., 1, 175, 10.1146/annurev-chembioeng-073009-100948 Bal, 2010, Advances in transcutaneous vaccine delivery: do all ways lead to Rome?, J. Control. Release, 148, 266, 10.1016/j.jconrel.2010.09.018 Mittal, 2013, Particle based vaccine formulations for transcutaneous immunization, Hum. Vaccin. Immunother., 9, 1950, 10.4161/hv.25217 des Rieux, 2006, Nanoparticles as potential oral delivery systems of proteins and vaccines: a mechanistic approach, J. Control. Release, 116, 1, 10.1016/j.jconrel.2006.08.013 De Geest, 2012, Surface-engineered polyelectrolyte multilayer capsules: synthetic vaccines mimicking microbial structure and function, Angew. Chem. Int. Ed., 51, 3862, 10.1002/anie.201200048 Irvine, 2013, Engineering synthetic vaccines using cues from natural immunity, Nat. Mater., 12, 978, 10.1038/nmat3775 Jiskoot, 2012, Protein instability and immunogenicity: roadblocks to clinical application of injectable protein delivery systems for sustained release, J. Pharm. Sci., 101, 946, 10.1002/jps.23018 Giri, 2011, Stabilization of proteins by nanoencapsulation in sugar–glass for tissue engineering and drug delivery applications, Adv. Mater., 23, 4861, 10.1002/adma.201102267 Correia-Pinto, 2013, Vaccine delivery carriers: insights and future perspectives, Int. J. Pharm., 440, 27, 10.1016/j.ijpharm.2012.04.047 Campbell, 2012, Objective assessment of nanoparticle disposition in mammalian skin after topical exposure, J. Control. Release, 162, 201, 10.1016/j.jconrel.2012.06.024 Mahe, 2009, Nanoparticle-based targeting of vaccine compounds to skin antigen-presenting cells by hair follicles and their transport in mice, J. Invest. Dermatol., 129, 1156, 10.1038/jid.2008.356 Mittal, 2013, Non-invasive delivery of nanoparticles to hair follicles: a perspective for transcutaneous immunization, Vaccine, 31, 3442, 10.1016/j.vaccine.2012.12.048 Mittal, 2014, Efficient nanoparticle-mediated needle-free transcutaneous vaccination via hair follicles requires adjuvantation, Nanomed. Nanotechnol. Biol. Med., 11, 147, 10.1016/j.nano.2014.08.009 Traul, 2000, Review of the toxicologic properties of medium-chain triglycerides, Food Chem. Toxicol., 38, 79, 10.1016/S0278-6915(99)00106-4 Ebensen, 2011, Bis-(3′,5′)-cyclic dimeric adenosine monophosphate: strong Th1/Th2/Th17 promoting mucosal adjuvant, Vaccine, 29, 5210, 10.1016/j.vaccine.2011.05.026 Seder, 2008, T-cell quality in memory and protection: implications for vaccine design (vol 8, pg 247, 2008), Nat. Rev. Immunol., 8 Ebensen, 2007, The bacterial second messenger cdiGMP exhibits promising activity as a mucosal adjuvant, Clin. Vaccine Immunol., 14, 952, 10.1128/CVI.00119-07 Sanchez, 2014, Intranasal delivery of influenza rNP adjuvanted with c-di-AMP induces strong humoral and cellular immune responses and provides protection against virus challenge, PLoS One, 9, e104824, 10.1371/journal.pone.0104824 Libanova, 2010, The member of the cyclic di-nucleotide family bis-(3′,5′)-cyclic dimeric inosine monophosphate exerts potent activity as mucosal adjuvant, Vaccine, 28, 2249, 10.1016/j.vaccine.2009.12.045 Pedersen, 2011, Evaluation of the sublingual route for administration of influenza H5N1 virosomes in combination with the bacterial second messenger c-di-GMP, PLoS One, 6, e26973, 10.1371/journal.pone.0026973 Zhao, 2014, Nanoparticle vaccines, Vaccine, 32, 327, 10.1016/j.vaccine.2013.11.069 Slutter, 2011, Adjuvant effect of cationic liposomes and CpG depends on administration route, J. Control. Release, 154, 123, 10.1016/j.jconrel.2011.02.007 Shu, 2012, Structure of STING bound to cyclic di-GMP reveals the mechanism of cyclic dinucleotide recognition by the immune system, Nat. Struct. Mol. Biol., 19, 722, 10.1038/nsmb.2331 Burdette, 2011, STING is a direct innate immune sensor of cyclic di-GMP, Nature, 478, 515, 10.1038/nature10429 McWhirter, 2009, A host type I interferon response is induced by cytosolic sensing of the bacterial second messenger cyclic-di-GMP, J. Exp. Med., 206, 1899, 10.1084/jem.20082874 Blaauboer, 2014, MPYS/STING-mediated TNF-alpha, not type I IFN, is essential for the mucosal adjuvant activity of (3′–5′)-cyclic-di-guanosine-monophosphate in vivo, J. Immunol., 192, 492, 10.4049/jimmunol.1301812 Oyewumi, 2010, Nano-microparticles as immune adjuvants: correlating particle sizes and the resultant immune responses, Expert Rev. Vaccines, 9, 1095, 10.1586/erv.10.89 Sayin, 2008, Mono-N-carboxymethyl chitosan (MCC) and N-trimethyl chitosan (TMC) nanoparticles for non-invasive vaccine delivery, Int. J. Pharm., 363, 139, 10.1016/j.ijpharm.2008.06.029 Carvalho, 2010, Surfactant systems for nasal zidovudine delivery: structural, rheological and mucoadhesive properties, J. Pharm. Pharmacol., 62, 430, 10.1211/jpp.62.04.0004 Raber, 2014, Quantification of nanoparticle uptake into hair follicles in pig ear and human forearm, J. Control. Release, 179C, 25, 10.1016/j.jconrel.2014.01.018 Fischer, 2009, Concomitant delivery of a CTL-restricted peptide antigen and CpG ODN by PLGA microparticles induces cellular immune response, J. Drug Target., 17, 652, 10.1080/10611860903119656 Blander, 2006, Toll-dependent selection of microbial antigens for presentation by dendritic cells, Nature, 440, 808, 10.1038/nature04596 Moresi, 1997, Distribution of Langerhans cells in human hair follicle, J. Cutan. Pathol., 24, 636, 10.1111/j.1600-0560.1997.tb01095.x Igyarto, 2011, Skin-resident murine dendritic cell subsets promote distinct and opposing antigen-specific T helper cell responses, Immunity, 35, 260, 10.1016/j.immuni.2011.06.005 Kidd, 2003, Th1/Th2 balance: the hypothesis, its limitations, and implications for health and disease, Altern. Med. Rev., 8, 223 Khader, 2009, Th17 cells at the crossroads of innate and adaptive immunity against infectious diseases at the mucosa, Mucosal Immunol., 2, 403, 10.1038/mi.2009.100 Broere, 2011, A2 T cell subsets and T cell-mediated immunity, 15 Podda, 2001, The adjuvanted influenza vaccines with novel adjuvants: experience with the MF59-adjuvanted vaccine, Vaccine, 19, 2673, 10.1016/S0264-410X(00)00499-0 Lindblad, 2000, Freund's Adjuvants, 49 Galli, 2009, Adjuvanted H5N1 vaccine induces early CD4+ T cell response that predicts long-term persistence of protective antibody levels, Proc. Natl. Acad. Sci. U. S. A., 106, 3877, 10.1073/pnas.0813390106 Seubert, 2008, The adjuvants aluminum hydroxide and MF59 induce monocyte and granulocyte chemoattractants and enhance monocyte differentiation toward dendritic cells, J. Immunol., 180, 5402, 10.4049/jimmunol.180.8.5402 Calabro, 2011, Vaccine adjuvants alum and MF59 induce rapid recruitment of neutrophils and monocytes that participate in antigen transport to draining lymph nodes, Vaccine, 29, 1812, 10.1016/j.vaccine.2010.12.090 Kalvodova, 2010, Squalene-based oil-in-water emulsion adjuvants perturb metabolism of neutral lipids and enhance lipid droplet formation, Biochem. Biophys. Res. Commun., 393, 350, 10.1016/j.bbrc.2009.12.062 Vono, 2013, The adjuvant MF59 induces ATP release from muscle that potentiates response to vaccination, Proc. Natl. Acad. Sci. U. S. A., 110, 21095, 10.1073/pnas.1319784110 Cruz, 2007, ATP activates a reactive oxygen species-dependent oxidative stress response and secretion of proinflammatory cytokines in macrophages, J. Biol. Chem., 282, 2871, 10.1074/jbc.M608083200 Cassel, 2009, The NLRP3 inflammasome: a sensor of immune danger signals, Semin. Immunol., 21, 194, 10.1016/j.smim.2009.05.002 Tang, 2010, The T helper type 2 response to cysteine proteases requires dendritic cell-basophil cooperation via ROS-mediated signaling, Nat. Immunol., 11, 608, 10.1038/ni.1883 Petrovsky, 2004, Vaccine adjuvants: current state and future trends, Immunol. Cell Biol., 82, 488, 10.1111/j.0818-9641.2004.01272.x Stills, 2005, Adjuvants and antibody production: dispelling the myths associated with Freund's complete and other adjuvants, ILAR J., 46, 280, 10.1093/ilar.46.3.280 Moreira, 2008, Modulation of adaptive immunity by different adjuvant-antigen combinations in mice lacking Nod2, Vaccine, 26, 5808, 10.1016/j.vaccine.2008.08.038 Billiau, 2001, Modes of action of Freund's adjuvants in experimental models of autoimmune diseases, J. Leukoc. Biol., 70, 849, 10.1189/jlb.70.6.849 Heath, 2004, Cross-presentation, dendritic cell subsets, and the generation of immunity to cellular antigens, Immunol. Rev., 199, 9, 10.1111/j.0105-2896.2004.00142.x Seder, 2008, T-cell quality in memory and protection: implications for vaccine design, Nat. Rev. Immunol., 8, 247, 10.1038/nri2274 Almeida, 2007, Superior control of HIV-1 replication by CD8+ T cells is reflected by their avidity, polyfunctionality, and clonal turnover, J. Exp. Med., 204, 2473, 10.1084/jem.20070784 Darrah, 2010, IL-10 production differentially influences the magnitude, quality, and protective capacity of Th1 responses depending on the vaccine platform, J. Exp. Med., 207, 1421, 10.1084/jem.20092532 Darrah, 2007, Multifunctional TH1 cells define a correlate of vaccine-mediated protection against Leishmania major, Nat. Med., 13, 843, 10.1038/nm1592 Graw, 2014, Predicting the impact of CD8+ T cell polyfunctionality on HIV disease progression, J. Virol., 88, 10134, 10.1128/JVI.00647-14 Kannanganat, 2007, Multiple-cytokine-producing antiviral CD4 T cells are functionally superior to single-cytokine-producing cells, J. Virol., 81, 8468, 10.1128/JVI.00228-07 Morrison, 2000, Immunity to murine Chlamydia trachomatis genital tract reinfection involves B cells and CD4+ T cells but not CD8+ T cells, Infect. Immun., 68, 6979, 10.1128/IAI.68.12.6979-6987.2000 Kaveh, 2011, Systemic BCG immunization induces persistent lung mucosal multifunctional CD4 T(EM) cells which expand following virulent mycobacterial challenge, PLoS One, 6, e21566, 10.1371/journal.pone.0021566